In Vitro Efficacy of Povidone-Iodine

Nasal And Oral Antiseptic Preparations

Against Severe Acute Respiratory

Syndrome-Coronavirus 2

(SARS-CoV-2)

Jesse Pelletier, 

Ocean Ophthalmology Group 

Belachew Tessema, 

ProHealth Physicians Ear, Nose and Throat

and University of Connecticut,

Department of Otolaryngology 

Jonna Westover,

The Institute for Antiviral Research at Utah State University 

Samantha Frank, 

University of Connecticut,

Department of Otolaryngology 

Seth Brown,

ProHealth Physicians Ear, Nose and Throat

and University of Connecticut,

Department of Otolaryngology 

Joseph Capriotti

Veloce BioPharma

This article is a “preprint”.Preprints are

studies destined for peer-reviewed journals

that have yet to be peer-reviewed.

Because COVID-19 is such a rapidly evolving

disease and peer-review takes so long,

most of the information circulating about

the disease comes from preprints.

Acknowledgement:

This article and Abstract

remain the property of

its authors

"As little as 0.5% povidone-iodine

completely inactivated the virus in 60

seconds, comparable to 70% alcohol.

Greater concentrations were equally

effective but provided no additional benefit."

Please download the full study here --------->

Link to the study here

Abstract

Introduction:

 

Improved antisepsis of human and non-human surfaces has been identified as a key feature of transmission reduction. There are no previous studies of povidone-iodine (PVP-I) against SARS-CoV-2. This study evaluated nasal and oral antiseptic formulations of povidone-iodine (PVP-I) for virucidal activity against SARS-CoV-2. This is the first report on the efficacy of PVP-I against the virus that causes COVID-19.

 

Methods:

 

PVP-I nasal antiseptic formulations and PVP-I oral rinse antiseptic formulations from 1-5% concentrations as well as controls were studied for virucidal efficacy against the SARS-CoV-2 virus. Test compounds were evaluated for ability to inactivate SARS-CoV-2 as measured in a virucidal assay. SARS-CoV-2 was exposed directly to the test compound for 60 seconds, compounds were then neutralized and surviving virus was quantified.

 

Results:

 

All concentrations of nasal antiseptics and oral rinse antiseptics evaluated completely inactivated the SARS-CoV-2 virus.

 

Conclusions:

 

Nasal and oral PVP-I antiseptic solutions are effective at inactivating the SARS-CoV-2 virus at a variety of concentrations after 60s exposure times. The formulations tested may help to reduce the transmission of SARS-CoV-2 if used for nasal decontamination, oral decontamination or surface decontamination in known or suspected cases of COVID-19.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

No external funding was provided.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.